Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia
Matthew S. Simon(NewYork–Presbyterian Hospital), Laura A. Kirkman(Office of Infectious Diseases), Joseph E. Visone, Alexis Dziedziech(Centre National de la Recherche Scientifique), Audrey N. Schuetz(Mayo Clinic), Richard R. Furman(Cornell University), Stephen G. Jenkins(NewYork–Presbyterian Hospital), Lars F. Westblade(NewYork–Presbyterian Hospital)
Cited by 92
Related Papers
Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
|Clinical Infectious Diseases|2016|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k